Prev Close | 31.76 |
Open | 31.53 |
Day Low/High | 31.20 / 32.10 |
52 Wk Low/High | 23.55 / 68.19 |
Volume | 20.27K |
Prev Close | 31.76 |
Open | 31.53 |
Day Low/High | 31.20 / 32.10 |
52 Wk Low/High | 23.55 / 68.19 |
Volume | 20.27K |
Exchange | NASDAQ |
Shares Outstanding | 12.36B |
Market Cap | 396.95M |
P/E Ratio | N/A |
Div & Yield | N.A. (N.A) |
Barron's big-name money managers did not pick many winners for the year.
Barron's big-name money managers did not pick many winners for the year.
Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.
Small-caps also should benefit from reduced corporate income taxes and strong U.S. economic growth.
Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.
From ANI Pharmaceuticals to T2 Biosystems, these names look good.
Celgene, ANI and T2 are seeing attractive entry points.
LGI Homes, ANI Pharmaceuticals and Sonus Networks are worth considering.
The oversold biotech sector is recovering.
My 4-Tier approach to deploying new capital in the sector.
Stocks are trading in a relatively narrow range, but are slightly down after Federal Reserve chair Janet Yellen hinted at a possible December rate hike. Still, her remarks are only having a minor impact on the market given the many Fed "head fakes" ...
Good morning! Bret Jensen here. I'm happy to be filling in for Doug Kass during this last trading day of October. It's been a good month for investors after a very bumpy August and September. All the major indices are up nicely for the month, despit...
These stocks should all show solid third-quarter results.
A so-called "pyramid strategy" can help you enter the depressed sector.
Some smaller biotechs offer good value at current levels.
Does anyone think efforts to inject more government into the private health care market will go anywhere?
Does anyone think efforts to inject more government into the private health care market will go anywhere?
I have about 25% in cash; if the market falls 5-10%, I'm in.
The sun could come out tomorrow for this small, depressed biotech.
But investors are likely to be wary ahead of the Fed meeting.
Have it ready in case market turns volatile.
Stay focused on price and remember that the market's riding a trend.
The upward move that began in mid-October has become, at best, a sideways move.